Schering gets EU OK to buy Organon

Schering-Plough has to give a little to get a lot. The company has agreed to sell off more than 20 of its animal vaccines and medicines to win regulatory approval to buy Organon Biosciences. The $14.4 billion deal will give Schering a stable of women's health meds and central nervous system drugs, and will bolster its late-stage pipeline, too.

Among the products to be sold are vaccines for E. coli in swine, flu and tetanus in horses, and rabies in several species. They also include veterinary antibiotics, insulin, and more.

- read the report from at

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?